US Market Is Still Waiting for Biosimilars to Produce Meaningful Price Reductions

March 14, 2019 – When the FDA approved its first biosimilar drug in 20151 – filgrastim-sndz, for compromised white blood cell count – there was talk of the benefits of competition in the pharma industry; increased access to medications for patients; and, of course, the all-around savings. After all, the cost of developing and guiding a biosimilar through the approval process is a fraction of the cost of developing a reference biologic: in the range of $100 million to $250 … (leggi tutto)